retatrutide phase 2 obesity nejm 2023 jastreboff trial results just delivered the first top-line 3 for a triple agonist in — and the findings from TRIUMPH-4 are striking👇 retatrutide phase 2 nejm 2023 – retatrutide phase 2 obesity nejm

Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours

Instead of stacking multiple tissue-repair compounds, it pairs a single potent fat-loss compound with a single potent regenerative compound, creating a clean two-compound protocol that is easy to manage and well-supported by available research data

This ability to close the gap between oral and needle-based therapies is the ultimate proof of liposomal vs chelated iron efficacy, proving that advanced encapsulation can achieve IV-like clinical outcomes that traditional chelated minerals simply cannot replicate

Lyophilized Storage -20C in dry, dark conditions for 12+ months